-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027...
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...
-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study...
-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.77%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.80%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.98%. June E-mini S&P futures...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals,...